{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:23:18Z","timestamp":1792095798269,"version":"4.4.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10928-025-09992-5","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T18:19:07Z","timestamp":1757009947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concentration-dependent blood binding: assessing implications through physiologically based Pharmacokinetic modeling of tacrolimus as a case example"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8365-6528","authenticated-orcid":false,"given":"Eman","family":"El-Khateeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeyen","family":"Karsanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Darwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Rostami-Hodjegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"2","key":"9992_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11095-022-03172-7","volume":"39","author":"SG Summerfield","year":"2022","unstructured":"Summerfield SG, Yates JWT, Fairman DA (2022) Free drug theory - no longer just a hypothesis?? Pharm Res 39(2):213\u2013222. https:\/\/doi.org\/10.1007\/s11095-022-03172-7","journal-title":"Pharm Res"},{"issue":"3","key":"9992_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/clpt.2008.216","volume":"85","author":"R Orlando","year":"2009","unstructured":"Orlando R, De Martin S, Pegoraro P, Quintieri L, Palatini P (2009) Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function. Clin Pharmacol Ther 85(3):319\u2013326. https:\/\/doi.org\/10.1038\/clpt.2008.216","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"9992_CR3","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1111\/bcp.13432","volume":"83","author":"S Schalkwijk","year":"2017","unstructured":"Schalkwijk S, Greupink R, Burger D (2017) Free dug concentrations in pregnancy: bound to measure unbound? Br J Clin Pharmacol 83(12):2595\u20132598. https:\/\/doi.org\/10.1111\/bcp.13432","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"9992_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1365-2125.1994.tb04251.x","volume":"37","author":"PE Rolan","year":"1994","unstructured":"Rolan PE (1994) Plasma protein binding displacement interactions\u2013why are they still regarded as clinically important? Br J Clin Pharmacol 37(2):125\u2013128. https:\/\/doi.org\/10.1111\/j.1365-2125.1994.tb04251.x","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"9992_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40262-017-0549-x","volume":"57","author":"H T\u2019Jollyn","year":"2018","unstructured":"T\u2019Jollyn H, Vermeulen A, Van Bocxlaer J, Colin P (2018) A physiologically based pharmacokinetic perspective on the clinical utility of albumin-based dose adjustments in critically ill patients. Clin Pharmacokinet 57(1):59\u201369. https:\/\/doi.org\/10.1007\/s40262-017-0549-x","journal-title":"Clin Pharmacokinet"},{"issue":"10\u201311","key":"9992_CR6","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1080\/00498250701658296","volume":"37","author":"M Baker","year":"2007","unstructured":"Baker M, Parton T (2007) Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake. Xenobiotica 37(10\u201311):1110\u20131134. https:\/\/doi.org\/10.1080\/00498250701658296","journal-title":"Xenobiotica"},{"issue":"6","key":"9992_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1124\/dmd.124.001645","volume":"52","author":"Z Yan","year":"2024","unstructured":"Yan Z, Ma L, Hwang N, Huang J, Kenny JR, Hop C (2024) Using the dynamic well-stirred model to extrapolate hepatic clearance of OATP substrates without assuming albumin-mediated hepatic drug uptake. Drug Metab Dispos 52(6):548\u2013554. https:\/\/doi.org\/10.1124\/dmd.124.001645","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"9992_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","volume":"57","author":"WJ Jusko","year":"1995","unstructured":"Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, Lee CC, Schechter P, Mekki QA (1995) Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 57(3):281\u2013290. https:\/\/doi.org\/10.1016\/0009-9236(95)90153-1","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"9992_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/j.1552-4604.1987.tb02192.x","volume":"27","author":"I Zaghloul","year":"1987","unstructured":"Zaghloul I, Ptachcinski RJ, Burckart GJ, Van Thiel D, Starzel TE, Venkataramanan R (1987) Blood protein binding of cyclosporine in transplant patients. J Clin Pharmacol 27(3):240\u2013242. https:\/\/doi.org\/10.1002\/j.1552-4604.1987.tb02192.x","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"9992_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/00498250701678955","volume":"38","author":"Q Chen","year":"2008","unstructured":"Chen Q, Tung EC, Ciccotto SL, Strauss JR, Ortiga R, Ramsay KA, Tang W (2008) Effect of the anticoagulant ethylenediamine tetra-acetic acid (EDTA) on the estimation of pharmacokinetic parameters: a case study with Tigecycline and Ciprofloxacin. Xenobiotica 38(1):76\u201386. https:\/\/doi.org\/10.1080\/00498250701678955","journal-title":"Xenobiotica"},{"issue":"6","key":"9992_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/00001813-200307000-00003","volume":"14","author":"HJ Bongard","year":"2003","unstructured":"Bongard HJ, Pluim D, Waardenburg RC, Ravic M, Beijnen JH, Schellens JH (2003) In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood. Anticancer Drugs 14(6):405\u2013410. https:\/\/doi.org\/10.1097\/00001813-200307000-00003","journal-title":"Anticancer Drugs"},{"issue":"4","key":"9992_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s002800000215","volume":"47","author":"L van Zuylen","year":"2001","unstructured":"van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A (2001) Pharmacokinetic modeling of Paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 47(4):309\u2013318. https:\/\/doi.org\/10.1007\/s002800000215","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"9992_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.18433\/j3qg7z","volume":"16","author":"CS Yue","year":"2013","unstructured":"Yue CS, Huynh HH, Raymond C, Charbonneau L, Roy L (2013) Population pharmacokinetic and pharmacodynamic modeling of acetazolamide in peritoneal dialysis patients and healthy volunteers. J Pharm Pharm Sci 16(1):89\u201398. https:\/\/doi.org\/10.18433\/j3qg7z","journal-title":"J Pharm Pharm Sci"},{"key":"9992_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ejps.2018.07.004","volume":"122","author":"RL Nation","year":"2018","unstructured":"Nation RL, Theuretzbacher U, Tsuji BT, International Society of Anti-, Infective P (2018) Concentration-dependent plasma protein binding: expect the unexpected. Eur J Pharm Sci 122:341\u2013346. https:\/\/doi.org\/10.1016\/j.ejps.2018.07.004","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"9992_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199120060-00001","volume":"20","author":"TM Ludden","year":"1991","unstructured":"Ludden TM (1991) Nonlinear pharmacokinetics: clinical implications. Clin Pharmacokinet 20(6):429\u2013446. https:\/\/doi.org\/10.2165\/00003088-199120060-00001","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"9992_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/bf01061777","volume":"21","author":"WR Gillespie","year":"1993","unstructured":"Gillespie WR (1993) Generalized pharmacokinetic modeling for drugs with nonlinear binding: I. Theoretical framework. J Pharmacokinet Biopharm 21(1):99\u2013124. https:\/\/doi.org\/10.1007\/bf01061777","journal-title":"J Pharmacokinet Biopharm"},{"issue":"1","key":"9992_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00007691-198810010-00004","volume":"10","author":"B Legg","year":"1988","unstructured":"Legg B, Gupta SK, Rowland M (1988) A model to account for the variation in cyclosporin binding to plasma lipids in transplant patients. Ther Drug Monit 10(1):20\u201327","journal-title":"Ther Drug Monit"},{"issue":"5","key":"9992_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10928-006-9021-5","volume":"33","author":"AS Zandvliet","year":"2006","unstructured":"Zandvliet AS, Schellens JHM, Copalu W, Beijnen JH, Huitema ADR (2006) A Semi-Physiological population Pharmacokinetic model describing the Non-linear disposition of indisulam. J Pharmacokinet Pharmacodyn 33(5):543\u2013570. https:\/\/doi.org\/10.1007\/s10928-006-9021-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"9992_CR19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.xphs.2017.09.006","volume":"107","author":"C Dorn","year":"2018","unstructured":"Dorn C, Kratzer A, Liebchen U, Schleibinger M, Murschhauser A, Schlossmann J, Kees F, Simon P, Kees MG (2018) Impact of experimental variables on the protein binding of Tigecycline in human plasma as determined by ultrafiltration. J Pharm Sci 107(2):739\u2013744. https:\/\/doi.org\/10.1016\/j.xphs.2017.09.006","journal-title":"J Pharm Sci"},{"issue":"12","key":"9992_CR20","first-page":"1644","volume":"29","author":"KE Kenworthy","year":"2001","unstructured":"Kenworthy KE, Clarke SE, Andrews J, Houston JB (2001) Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 29(12):1644\u20131651","journal-title":"Drug Metab Dispos"},{"key":"9992_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1475-2875-6-67","volume":"6","author":"IA Carneiro","year":"2007","unstructured":"Carneiro IA, Drakeley CJ, Owusu-Agyei S, Mmbando B, Chandramohan D (2007) Haemoglobin and haematocrit: is the threefold conversion valid for assessing anaemia in malaria-endemic settings? Malar J 6:67. https:\/\/doi.org\/10.1186\/1475-2875-6-67","journal-title":"Malar J"},{"issue":"1","key":"9992_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.hemonc.2016.08.007","volume":"11","author":"S Kambali","year":"2018","unstructured":"Kambali S, Taj A (2018) Polycythemia vera masked due to severe iron deficiency anemia. Hematol Oncol Stem Cell Ther 11(1):38\u201340. https:\/\/doi.org\/10.1016\/j.hemonc.2016.08.007","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"9992_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2193-9616-1-9","volume":"1","author":"M Jamei","year":"2013","unstructured":"Jamei M, Marciniak S, Edwards D, Wragg K, Feng K, Barnett A, Rostami-Hodjegan A (2013) The simcyp population based simulator: architecture, implementation, and quality assurance. Silico Pharmacol 1:9\u20139","journal-title":"Silico Pharmacol"},{"issue":"2","key":"9992_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/bdd.1776","volume":"33","author":"A Rostami-Hodjegan","year":"2012","unstructured":"Rostami-Hodjegan A, Tamai I, Pang KS (2012) Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay! Biopharm Drug Dispos 33(2):47\u201350. https:\/\/doi.org\/10.1002\/bdd.1776","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"9992_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/clpt.2012.68","volume":"92","author":"P Zhao","year":"2012","unstructured":"Zhao P, Rowland M, Huang SM (2012) Best practice in the use of physiologically based Pharmacokinetic modeling and simulation to address clinical Pharmacology regulatory questions. Clin Pharmacol Ther 92(1):17\u201320. https:\/\/doi.org\/10.1038\/clpt.2012.68","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"9992_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/bdd.2257","volume":"42","author":"E El-Khateeb","year":"2021","unstructured":"El-Khateeb E, Burkhill S, Murby S, Amirat H, Rostami\u2010Hodjegan A, Ahmad A (2021) Physiological\u2010based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20\u2010years; in\u2010depth analysis of applications, organizations, and platforms. Biopharm Drug Dispos 42(4):107\u2013117. https:\/\/doi.org\/10.1002\/bdd.2257","journal-title":"Biopharm Drug Dispos"},{"key":"9992_CR27","doi-asserted-by":"publisher","unstructured":"Rostami-Hodjegan A, Bois FY (2021) Opening a debate on open-source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate. CPT Pharmacometrics Syst Pharmacol 10(5):420\u2013427. https:\/\/doi.org\/10.1002\/psp4.12615","DOI":"10.1002\/psp4.12615"},{"issue":"3","key":"9992_CR28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/bdd.2357","volume":"44","author":"AJ Rajput","year":"2023","unstructured":"Rajput AJ, Aldibani HKA, Rostami-Hodjegan A (2023) In-depth analysis of patterns in selection of different physiologically based pharmacokinetic modeling tools: part I - applications and rationale behind the use of open source-code software. Biopharm Drug Dispos 44(3):274\u2013285. https:\/\/doi.org\/10.1002\/bdd.2357","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"9992_CR29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/bdd.2360","volume":"44","author":"HKA Aldibani","year":"2023","unstructured":"Aldibani HKA, Rajput AJ, Rostami-Hodjegan A (2023) In\u2010depth analysis of patterns in selection of different physiologically\u2010based pharmacokinetic modeling tools: part II\u2014assessment of model reusability and comparison between open and non\u2010open source\u2010code software. Biopharm Drug Dispos 44(4):292\u2013300","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"9992_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1208\/s12248-024-00897-8","volume":"26","author":"L Fang","year":"2024","unstructured":"Fang L, Gong Y, Hooker AC, Lukacova V, Rostami-Hodjegan A, Sale M, Grosser S, Jereb R, Savic R, Peck C, Zhao L (2024) The role of model master files for sharing, acceptance, and communication with FDA. AAPS J 26(2):28. https:\/\/doi.org\/10.1208\/s12248-024-00897-8","journal-title":"AAPS J"},{"issue":"5","key":"9992_CR31","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/psp4.12907","volume":"12","author":"F Wu","year":"2023","unstructured":"Wu F, Mousa Y, Raines K, Bode C, Tsang YC, Cristofoletti R, Zhang H, Heimbach T, Fang L, Kesisoglou F, Mitra A, Polli J, Kim MJ, Fan J, Zolnik BS, Sun D, Zhang Y, Zhao L (2023) Regulatory utility of physiologically-based Pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report. CPT Pharmacometrics Syst Pharmacol 12(5):585\u2013597. https:\/\/doi.org\/10.1002\/psp4.12907","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"9992_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/psp4.12392","volume":"8","author":"C Emoto","year":"2019","unstructured":"Emoto C, Johnson TN, Hahn D, Christians U, Alloway RR, Vinks AA, Fukuda T (2019) A theoretical Physiologically-Based Pharmacokinetic approach to ascertain covariates explaining the large interpatient variability in tacrolimus disposition. CPT Pharmacometrics Syst Pharmacol 8(5):273\u2013284. https:\/\/doi.org\/10.1002\/psp4.12392","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"9992_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0022-3565(24)37815-2","volume":"287","author":"R Kawai","year":"1998","unstructured":"Kawai R, Mathew D, Tanaka C, Rowland M (1998) Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther 287(2):457\u2013468","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"9992_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1023\/a:1020978509566","volume":"27","author":"C Tanaka","year":"1999","unstructured":"Tanaka C, Kawai R, Rowland M (1999) Physiologically based pharmacokinetics of cyclosporine A: reevaluation of dose-nonlinear kinetics in rats. J Pharmacokinet Biopharm 27(6):597\u2013623. https:\/\/doi.org\/10.1023\/a:1020978509566","journal-title":"J Pharmacokinet Biopharm"},{"key":"9992_CR35","doi-asserted-by":"publisher","first-page":"1200828","DOI":"10.3389\/fphar.2023.1200828","volume":"14","author":"F Alasmari","year":"2023","unstructured":"Alasmari F, Alasmari MS, Muwainea HM, Alomar HA, Alasmari AF, Alsanea S, Alshamsan A, Rasool MF, Alqahtani F (2023) Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing. Front Pharmacol 14:1200828. https:\/\/doi.org\/10.3389\/fphar.2023.1200828","journal-title":"Front Pharmacol"},{"key":"9992_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejps.2018.11.033","volume":"128","author":"V Balbas-Martinez","year":"2019","unstructured":"Balbas-Martinez V, Michelet R, Edginton AN, Meesters K, Troconiz IF, Vermeulen A (2019) Physiologically-based pharmacokinetic model for Ciprofloxacin in children with complicated urinary tract infection. Eur J Pharm Sci 128:171\u2013179. https:\/\/doi.org\/10.1016\/j.ejps.2018.11.033","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"9992_CR37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.healun.2004.02.022","volume":"24","author":"H Reichenspurner","year":"2005","unstructured":"Reichenspurner H (2005) Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 24(2):119\u2013130. https:\/\/doi.org\/10.1016\/j.healun.2004.02.022","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"9992_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/FTD.0b013e3181c0eecb","volume":"32","author":"HH van Rossum","year":"2010","unstructured":"van Rossum HH, de Fijter JW, van Pelt J (2010) Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. Ther Drug Monit 32(1):3\u201310. https:\/\/doi.org\/10.1097\/FTD.0b013e3181c0eecb","journal-title":"Ther Drug Monit"},{"issue":"5","key":"9992_CR39","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/00007691-200410000-00008","volume":"26","author":"H Zahir","year":"2004","unstructured":"Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ (2004) Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation. Ther Drug Monit 26(5):506\u2013515. https:\/\/doi.org\/10.1097\/00007691-200410000-00008","journal-title":"Ther Drug Monit"},{"issue":"3","key":"9992_CR40","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1046\/j.1365-2125.2003.02008.x","volume":"57","author":"H Zahir","year":"2003","unstructured":"Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ (2003) Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol 57(3):298\u2013309. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.02008.x","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"9992_CR41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40262-019-00854-1","volume":"59","author":"MA Sikma","year":"2020","unstructured":"Sikma MA, Van Maarseveen EM, Hunault CC, Moreno JM, Van de Graaf EA, Kirkels JH, Verhaar MC, Grutters JC, Kesecioglu J, De Lange DW, Huitema ADR (2020) Unbound plasma, total plasma, and Whole-Blood tacrolimus pharmacokinetics early after thoracic organ transplantation. Clin Pharmacokinet 59(6):771\u2013780. https:\/\/doi.org\/10.1007\/s40262-019-00854-1","journal-title":"Clin Pharmacokinet"},{"issue":"1\u20132","key":"9992_CR42","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jchromb.2006.12.048","volume":"850","author":"MJ Bogusz","year":"2007","unstructured":"Bogusz MJ, Enazi EA, Hassan H, Abdel-Jawaad J, Ruwaily JA, Tufail MA (2007) Simultaneous LC\u2013MS\u2013MS determination of cyclosporine A, tacrolimus, and sirolimus in whole blood as well as mycophenolic acid in plasma using common pretreatment procedure. J Chromatogr B 850(1\u20132):471\u2013480. https:\/\/doi.org\/10.1016\/j.jchromb.2006.12.048","journal-title":"J Chromatogr B"},{"issue":"3","key":"9992_CR43","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.ajkd.2017.10.020","volume":"71","author":"DRJ Kuypers","year":"2018","unstructured":"Kuypers DRJ (2018) Tacrolimus formulations and African American kidney transplant recipients: when do details matter?? Am J Kidney Dis 71(3):302\u2013305. https:\/\/doi.org\/10.1053\/j.ajkd.2017.10.020","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"9992_CR44","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1053\/j.ajkd.2017.07.018","volume":"71","author":"J Trofe-Clark","year":"2018","unstructured":"Trofe-Clark J, Brennan DC, West-Thielke P, Milone MC, Lim MA, Neubauer R, Nigro V, Bloom RD (2018) Results of ASERTAA, a randomized prospective crossover Pharmacogenetic study of Immediate-Release versus Extended-Release tacrolimus in African American kidney transplant recipients. Am J Kidney Dis 71(3):315\u2013326. https:\/\/doi.org\/10.1053\/j.ajkd.2017.07.018","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"9992_CR45","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/00007890-200105150-00021","volume":"71","author":"S Tuteja","year":"2001","unstructured":"Tuteja S, Alloway RR, Johnson JA, Gaber AO (2001) The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 71(9):1303\u20131307. https:\/\/doi.org\/10.1097\/00007890-200105150-00021","journal-title":"Transplantation"},{"issue":"1","key":"9992_CR46","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1124\/jpet.103.050716","volume":"306","author":"S Tamura","year":"2003","unstructured":"Tamura S, Tokunaga Y, Ibuki R, Amidon GL, Sezaki H, Yamashita S (2003) The site-specific transport and metabolism of tacrolimus in rat small intestine. J Pharmacol Exp Ther 306(1):310\u2013316. https:\/\/doi.org\/10.1124\/jpet.103.050716","journal-title":"J Pharmacol Exp Ther"},{"issue":"14","key":"9992_CR47","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/ajhp\/52.14.1521","volume":"52","author":"PA Kelly","year":"1995","unstructured":"Kelly PA, Burckart GJ, Venkataramanan R (1995) Tacrolimus: a new immunosuppressive agent. Am J Health-Syst Pharm 52(14):1521\u20131535. https:\/\/doi.org\/10.1093\/ajhp\/52.14.1521","journal-title":"Am J Health-Syst Pharm"},{"issue":"4","key":"9992_CR48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2165\/00003088-200140040-00004","volume":"40","author":"PE Wallemacq","year":"2001","unstructured":"Wallemacq PE, Verbeeck RK (2001) Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 40(4):283\u2013295. https:\/\/doi.org\/10.2165\/00003088-200140040-00004","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"9992_CR49","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/1043-6618(95)86427-X","volume":"25","author":"FS Chow","year":"1997","unstructured":"Chow FS, Piekoszewski W, Jusko WJ (1997) Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. Drug Metab Dispos 25(5):610\u2013616. https:\/\/doi.org\/10.1016\/1043-6618(95)86427-X","journal-title":"Drug Metab Dispos"},{"key":"9992_CR50","unstructured":"Billett HH (1990)\u00a0Hemoglobin and hematocrit. In: Walker HK, Hall WD, Hurst JW (eds) Clinical methods: The\u00a0history, physical, and laboratory examinations, 3rd edn. Butterworths, Boston, pp 718\u2013719"},{"issue":"9","key":"9992_CR51","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/bdd.777","volume":"32","author":"H Ohtani","year":"2011","unstructured":"Ohtani H, Barter Z, Minematsu T, Makuuchi M, Sawada Y, Rostami-Hodjegan A (2011) Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. Biopharm Drug Dispos 32(9):498\u2013506. https:\/\/doi.org\/10.1002\/bdd.777","journal-title":"Biopharm Drug Dispos"},{"issue":"7","key":"9992_CR52","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/bdd.2081","volume":"38","author":"VK Jogiraju","year":"2017","unstructured":"Jogiraju VK, Avvari S, Gollen R, Taft DR (2017) Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations. Biopharm Drug Dispos 38(7):426\u2013438. https:\/\/doi.org\/10.1002\/bdd.2081","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"9992_CR53","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.xphs.2017.12.024","volume":"107","author":"HS Purohit","year":"2018","unstructured":"Purohit HS, Trasi NS, Sun DD, Chow ECY, Wen H, Zhang X, Gao Y, Taylor LS (2018) Investigating the impact of drug crystallinity in amorphous tacrolimus capsules on pharmacokinetics and bioequivalence using discriminatory in vitro dissolution testing and physiologically based pharmacokinetic modeling and simulation. J Pharm Sci 107(5):1330\u20131341. https:\/\/doi.org\/10.1016\/j.xphs.2017.12.024","journal-title":"J Pharm Sci"},{"issue":"1","key":"9992_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1742-4682-5-19","volume":"5","author":"H Ando","year":"2008","unstructured":"Ando H, Izawa S, Hori W, Nakagawa I (2008) Utility of a single adjusting compartment: a novel methodology for whole body physiologically-based Pharmacokinetic modelling. Theor Biol Med Model 5(1):19\u201319. https:\/\/doi.org\/10.1186\/1742-4682-5-19","journal-title":"Theor Biol Med Model"},{"key":"9992_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2009.12.002","author":"K Rowland Yeo","year":"2010","unstructured":"Rowland Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A (2010) Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme Inhibition by parent compound and its metabolite in both liver and gut-The effect of diltiazem on the time-c. Eur J Pharm Sci. https:\/\/doi.org\/10.1016\/j.ejps.2009.12.002","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"9992_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/00007691-198801000-00003","volume":"10","author":"B Legg","year":"1988","unstructured":"Legg B, Rowland M (1988) Cyclesporin: erythrocyte binding and an examination of its use to estimate unbound concentration. Ther Drug Monit 10(1):16\u201319. https:\/\/doi.org\/10.1097\/00007691-198801000-00003","journal-title":"Ther Drug Monit"},{"issue":"5","key":"9992_CR57","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/jps.10128","volume":"91","author":"P Poulin","year":"2002","unstructured":"Poulin P, Theil F-P (2002) Prediction of pharmacokinetics prior to in vivo studies. Part II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91(5):1358\u20131370. https:\/\/doi.org\/10.1002\/jps.10128","journal-title":"J Pharm Sci"},{"issue":"4","key":"9992_CR58","doi-asserted-by":"publisher","first-page":"746","DOI":"10.2165\/00003495-199346040-00009","volume":"46","author":"DH Peters","year":"1993","unstructured":"Peters DH, Fitton A, Plosker GL, Faulds D (1993) Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 46(4):746\u2013794. https:\/\/doi.org\/10.2165\/00003495-199346040-00009","journal-title":"Drugs"},{"issue":"2","key":"9992_CR59","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.2042-7158.1994.tb03752.x","volume":"46","author":"K Nagase","year":"1994","unstructured":"Nagase K, Iwasaki K, Nozaki K, Noda K (1994) Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 46(2):113\u2013117. https:\/\/doi.org\/10.1111\/j.2042-7158.1994.tb03752.x","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"9992_CR60","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/bcpt.12914","volume":"122","author":"H Zhang","year":"2018","unstructured":"Zhang H, Bu F, Li L, Jiao Z, Ma G, Cai W, Zhuang X, Lin HS, Shin JG, Xiang X (2018) Prediction of drug\u2013drug interaction between tacrolimus and principal ingredients of Wuzhi capsule in Chinese healthy volunteers using physiologically-based pharmacokinetic modelling. Basic Clin Pharmacol Toxicol 122(3):331\u2013340. https:\/\/doi.org\/10.1111\/bcpt.12914","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"9992_CR61","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0090-9556(24)15298-1","volume":"27","author":"A M\u00f6ller","year":"1999","unstructured":"M\u00f6ller A, Iwasaki K, Kawamura A, Teramura Y, Shiraga T, Hata T, Sch\u00e4fer A, Undre NA (1999) The disposition of 14\u00a0C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos 27(6):633\u2013636","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"9992_CR62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1067\/mcp.2001.113183","volume":"69","author":"LM Mancinelli","year":"2001","unstructured":"Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ, Christians U (2001) The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 69(1):24\u201331. https:\/\/doi.org\/10.1067\/mcp.2001.113183","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9992_CR63","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1600-6143.2012.04308.x","volume":"13","author":"JC Krisl","year":"2013","unstructured":"Krisl JC, Fortier CR, Taber DJ (2013) Disruptions in the supply of medications used in transplantation: implications and management strategies for the transplant clinician. Am J Transplant 13(1):20\u201330. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04308.x","journal-title":"Am J Transplant"},{"issue":"5","key":"9992_CR64","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.3892\/etm.2019.7446","volume":"17","author":"D Wang","year":"2019","unstructured":"Wang D, Lu J, Li Q, Li Z (2019) Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models. Experimental Therapeutic Med 17(5):4023\u20134031. https:\/\/doi.org\/10.3892\/etm.2019.7446","journal-title":"Experimental Therapeutic Med"},{"issue":"1","key":"9992_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-20071-3","volume":"8","author":"JH Kim","year":"2018","unstructured":"Kim JH, Han N, Kim MG, Yun H-Y, Lee S, Bae E, Kim YS, Kim I-W, Oh JM (2018) Increased exposure of tacrolimus by Co-administered mycophenolate mofetil: population Pharmacokinetic analysis in healthy volunteers. Sci Rep 8(1):1\u20139. https:\/\/doi.org\/10.1038\/s41598-018-20071-3","journal-title":"Sci Rep"},{"issue":"5","key":"9992_CR66","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/jat.3412","volume":"37","author":"SJ Borghoff","year":"2017","unstructured":"Borghoff SJ, Ring C, Banton MI, Leavens TL (2017) Physiologically based Pharmacokinetic model for Ethyl tertiary-butyl ether and tertiary-butyl alcohol in rats: contribution of binding to \u03b12u-globulin in male rats and high-exposure nonlinear kinetics to toxicity and cancer outcomes. J Appl Toxicology: JAT 37(5):621\u2013640. https:\/\/doi.org\/10.1002\/jat.3412","journal-title":"J Appl Toxicology: JAT"},{"issue":"5","key":"9992_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1208\/s12248-020-00503-7","volume":"22","author":"MJ Dolton","year":"2020","unstructured":"Dolton MJ, Chiang PC, Ma F, Jin JY, Chen Y (2020) A physiologically based Pharmacokinetic model of vismodegib: deconvoluting the impact of saturable plasma protein binding, pH-Dependent solubility and Nonsink permeation. AAPS J 22(5):117. https:\/\/doi.org\/10.1208\/s12248-020-00503-7","journal-title":"AAPS J"},{"issue":"4","key":"9992_CR68","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1124\/dmd.120.000023","volume":"49","author":"S Koyama","year":"2021","unstructured":"Koyama S, Toshimoto K, Lee W, Aoki Y, Sugiyama Y (2021) Revisiting nonlinear Bosentan pharmacokinetics by physiologically based pharmacokinetic modeling: target binding, albeit not a major contributor to nonlinearity, can offer prediction of target occupancy. Drug Metab Dispos 49(4):298\u2013304. https:\/\/doi.org\/10.1124\/dmd.120.000023","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"9992_CR69","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1124\/dmd.123.001344","volume":"51","author":"Y Sugiyama","year":"2023","unstructured":"Sugiyama Y, Aoki Y (2023) A 20-year research overview: quantitative prediction of hepatic clearance using the in vitro-in vivo extrapolation approach based on physiologically based pharmacokinetic modeling and extended clearance concept. Drug Metab Dispos 51(9):1067\u20131076. https:\/\/doi.org\/10.1124\/dmd.123.001344","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"9992_CR70","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1124\/dmd.123.001403","volume":"51","author":"X Li","year":"2023","unstructured":"Li X, Jusko WJ (2023) Utility of minimal physiologically based pharmacokinetic models for assessing fractional distribution, oral absorption, and series-compartment models of hepatic clearance. Drug Metab Dispos 51(10):1403\u20131418. https:\/\/doi.org\/10.1124\/dmd.123.001403","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"9992_CR71","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1016\/j.xphs.2020.03.031","volume":"109","author":"A Sarashina","year":"2020","unstructured":"Sarashina A, Chiba K, Tatami S, Kato Y (2020) Physiologically based pharmacokinetic model of the DPP-4 inhibitor linagliptin to describe its nonlinear pharmacokinetics in humans. J Pharm Sci 109(7):2336\u20132344. https:\/\/doi.org\/10.1016\/j.xphs.2020.03.031","journal-title":"J Pharm Sci"},{"issue":"1","key":"9992_CR72","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1124\/dmd.110.035915","volume":"39","author":"F Zhang","year":"2011","unstructured":"Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, Dyer MA, Williams RT, Roussel MF, Nemeth K, Zhu F, Zhang J, Lu M, Panetta JC, Boulos N, Stewart CF (2011) Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos 39(1):15\u201321. https:\/\/doi.org\/10.1124\/dmd.110.035915","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"9992_CR73","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1124\/dmd.124.001711","volume":"52","author":"R Yu","year":"2024","unstructured":"Yu R, Jusko WJ (2024) Physiologically based pharmacokinetic modeling: the reversible metabolism and tissue-specific partitioning of Methylprednisolone and Methylprednisone in rats. Drug Metab Dispos 52(7):662\u2013672. https:\/\/doi.org\/10.1124\/dmd.124.001711","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"9992_CR74","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2253-2-5","volume":"2","author":"DG Levitt","year":"2002","unstructured":"Levitt DG (2002) PKQuest: volatile solutes - application to enflurane, nitrous oxide, halothane, methoxyflurane and toluene pharmacokinetics. BMC Anesthesiol 2(1):5\u20135. https:\/\/doi.org\/10.1186\/1471-2253-2-5","journal-title":"BMC Anesthesiol"},{"issue":"2","key":"9992_CR75","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0041-008x(92)90297-6","volume":"116","author":"DR Plowchalk","year":"1992","unstructured":"Plowchalk DR, Andersen ME, deBethizy JD (1992) A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. Toxicol Appl Pharmacol 116(2):177\u2013188. https:\/\/doi.org\/10.1016\/0041-008x(92)90297-6","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"9992_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17050590","volume":"17","author":"S Nolte","year":"2025","unstructured":"Nolte S, Swarte JC, Knobbe TJ, Nolte IM, Zijp TR, Moes HR, van Londen M, Riemersma NL, Bj\u00f6rk JR, Weersma RK, Drost G, Berger SP, Touw DJ, Bakker SJL (2025) Plasma versus whole blood tacrolimus concentrations and health-related quality of life in kidney transplant recipients. Pharmaceutics 17(5):590. https:\/\/doi.org\/10.3390\/pharmaceutics17050590","journal-title":"Pharmaceutics"},{"issue":"1","key":"9992_CR77","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s1056-8719(02)00158-2","volume":"46","author":"H Zahir","year":"2001","unstructured":"Zahir H, Nand RA, Brown KF, Tattam BN, McLachlan AJ (2001) Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods 46(1):27\u201335. https:\/\/doi.org\/10.1016\/s1056-8719(02)00158-2","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"1","key":"9992_CR78","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1085\/jgp.21.1.107","volume":"21","author":"T Teorell","year":"1937","unstructured":"Teorell T (1937) Studies on the diffusion effect upon ionic distribution: II. experiments on ionic accumulation. J Gen Physiol 21(1):107\u2013122","journal-title":"J Gen Physiol"},{"issue":"4","key":"9992_CR79","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40268-020-00323-2","volume":"20","author":"H Jun","year":"2020","unstructured":"Jun H, Rong Y, Yih C, Ho J, Cheng W, Kiang TK (2020) Comparisons of four protein-binding models characterizing the pharmacokinetics of unbound phenytoin in adult patients using non-linear mixed-effects modeling. Drugs R D 20(4):343\u2013358","journal-title":"Drugs R D"},{"issue":"8","key":"9992_CR80","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/psp4.12420","volume":"8","author":"K Itohara","year":"2019","unstructured":"Itohara K, Yano I, Tsuzuki T, Uesugi M, Nakagawa S, Yonezawa A, Okajima H, Kaido T, Uemoto S, Matsubara K (2019) A minimal Physiologically-Based Pharmacokinetic model for tacrolimus in Living\u2010Donor liver transplantation: perspectives related to liver regeneration and the cytochrome P450 3A5 (CYP3A5) genotype. CPT Pharmacometrics Syst Pharmacol 8(8):587\u2013595. https:\/\/doi.org\/10.1002\/psp4.12420","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"9992_CR81","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11095-014-1460-x","volume":"32","author":"H T\u2019jollyn","year":"2015","unstructured":"T\u2019jollyn H, Snoeys J, Colin P, Van Bocxlaer J, Annaert P, Cuyckens F, Vermeulen A, Van Peer A, Allegaert K, Mannens G, Boussery K (2015) Physiology-Based IVIVE predictions of Tramadol from in vitro metabolism data. Pharm Res 32(1):260\u2013274. https:\/\/doi.org\/10.1007\/s11095-014-1460-x","journal-title":"Pharm Res"},{"issue":"2","key":"9992_CR82","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrd2173","volume":"6","author":"A Rostami-Hodjegan","year":"2007","unstructured":"Rostami-Hodjegan A, Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6(2):140\u2013148. https:\/\/doi.org\/10.1038\/nrd2173","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"9992_CR83","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/17425255.2017.1395413","volume":"13","author":"LM Andrews","year":"2017","unstructured":"Andrews LM, Li Y, De Winter BCM, Shi Y-Y, Baan CC, Van Gelder T, Hesselink DA (2017) Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opin Drug Metab Toxicol 13(12):1225\u20131236. https:\/\/doi.org\/10.1080\/17425255.2017.1395413","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"9992_CR84","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1208\/s12248-020-00501-9","volume":"22","author":"LZ Benet","year":"2020","unstructured":"Benet LZ, Sodhi JK (2020) Investigating the theoretical basis for in Vitro\u2013In vivo extrapolation (IVIVE) in predicting drug metabolic clearance and proposing future experimental pathways. AAPS J 22(5):120. https:\/\/doi.org\/10.1208\/s12248-020-00501-9","journal-title":"AAPS J"},{"issue":"1","key":"9992_CR85","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/1574884710666150817104746","volume":"11","author":"R Mehvar","year":"2016","unstructured":"Mehvar R (2016) Application of organ clearance to estimation of the in vivo hepatic extraction ratio. Curr Clin Pharmacol 11(1):47\u201352","journal-title":"Curr Clin Pharmacol"},{"issue":"6","key":"9992_CR86","first-page":"2753","volume":"23","author":"M Machida","year":"1991","unstructured":"Machida M, Takahara S, Ishibashi M, Hayashi M, Sekihara T, Yamanaka H (1991) Effect of temperature and hematocrit on plasma concentration of FK 506. Transplant Proc 23(6):2753\u20132754","journal-title":"Transplant Proc"},{"issue":"10","key":"9992_CR87","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1111\/bcp.14053","volume":"85","author":"R Ter Heine","year":"2019","unstructured":"Ter Heine R, Kane SP, Huitema ADR, Krasowski MD, van Maarseveen EM (2019) Nonlinear protein binding of phenytoin in clinical practice: development and validation of a mechanistic prediction model. Br J Clin Pharmacol 85(10):2360\u20132368. https:\/\/doi.org\/10.1111\/bcp.14053","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-025-09992-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:33:20Z","timestamp":1761154400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-025-09992-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["9992"],"URL":"https:\/\/doi.org\/10.1007\/s10928-025-09992-5","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EE-K and AR-H are employees of Certara Predictive Technologies and may hold shares in Certara.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"50"}}